Новости Карабулака за 25.05.2021

Excessive capital requirement and myriad of other complexities associated with the discovery of biologics have prompted drug developers to adopt in silico tools / techniques to expedite the discovery timelines

Over the years, extensive R&D efforts have enabled microbiome-based therapy / diagnostic developers to make significant strides, in terms of progressing proprietary product candidates into the clinic.